Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells

Area of Science:

• Biotechnology
• Immunotherapy
• Gene Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapies offer transformative potential for hematological malignancies and solid tumors.
• Current CAR T-cell therapy limitations include high costs, complex manufacturing, long wait times, and unequal access.
• There is a critical need for simplified, accessible CAR T-cell generation strategies.

Purpose of the Study:

• To develop and validate a novel methylcellulose-based microfoam for rapid CAR T-cell generation.
• To assess the efficiency of CAR gene transfer and in vivo anti-tumor efficacy of microfoam-generated CAR T-cells.
• To establish proof of concept for a simplified, accessible cellular immunotherapy platform.

Main Methods:

• Development of a methylcellulose-based microfoam for colocalizing T cells and viral vectors.
• Subcutaneous administration of newly generated CAR T-cells in mouse xenograft models.
• Evaluation of CAR T-cell systemic dispersion, anti-tumor activity, and comparison to conventional CAR T-cell therapy.
• Assessment of the platform's operational requirements, including sterility, closed-system processing, and lack of prolonged cell culture or cleanroom facilities.

Main Results:

• The microfoam platform facilitates efficient CAR gene transfer by promoting T cell and vector colocalization.
• Subcutaneously administered CAR T-cells dispersed systemically and mediated regression of distal tumors in lymphoma and hepatocellular carcinoma models.
• Anti-tumor activity was comparable to conventionally manufactured CAR T-cells.
• The platform operates as a sterile closed system, eliminating the need for prolonged cell culture, centralized manufacturing, or cleanroom production.

Conclusions:

• A methylcellulose-based microfoam enables rapid, simplified generation of CAR T-cells for subcutaneous administration.
• This novel platform demonstrates efficient in vivo anti-tumor efficacy comparable to conventional methods.
• The findings suggest a potential to reduce manufacturing complexity and improve accessibility of CAR T-cell immunotherapies.